Editorial: Challenges and opportunities of TKIs in the treatment of NSCLC patients with uncommon mutations.
作者信息
Su Chunxia, Sun Shi-Yong
机构信息
Department of Oncology, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China.
Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA, United States.
出版信息
Front Oncol. 2022 Jul 26;12:970315. doi: 10.3389/fonc.2022.970315. eCollection 2022.
Abstract
摘要
相似文献
1
Editorial: Challenges and opportunities of TKIs in the treatment of NSCLC patients with uncommon mutations.社论：酪氨酸激酶抑制剂治疗非小细胞肺癌罕见突变患者的挑战与机遇
Front Oncol. 2022 Jul 26;12:970315. doi: 10.3389/fonc.2022.970315. eCollection 2022.
2
Effectiveness of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study.常见 EGFR 突变以外的晚期非小细胞肺癌患者中表皮生长因子受体酪氨酸激酶抑制剂的疗效：一项多中心观察性研究。
Thorac Cancer. 2021 Jan;12(1):90-96. doi: 10.1111/1759-7714.13718. Epub 2020 Oct 29.
3
Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.不同寻常的表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）在罕见 EGFR 突变患者中的反应：在这一复杂临床情况下的新见解和未来展望。
Int J Mol Sci. 2019 Mar 21;20(6):1431. doi: 10.3390/ijms20061431.
4
[A Review of EGFR-TKIs Therapy of Non-small Cell Lung Cancer
with Uncommon EGFR Mutations].[非小细胞肺癌罕见表皮生长因子受体（EGFR）突变的EGFR酪氨酸激酶抑制剂治疗综述]
Zhongguo Fei Ai Za Zhi. 2019 Sep 20;22(9):590-599. doi: 10.3779/j.issn.1009-3419.2019.09.07.
5
Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).优化表皮生长因子受体（EGFR）突变阳性非小细胞肺癌（NSCLC）中酪氨酸激酶抑制剂（TKI）的治疗顺序。
Lung Cancer. 2019 Nov;137:113-122. doi: 10.1016/j.lungcan.2019.09.017. Epub 2019 Sep 23.
6
The Predictive Values of Advanced Non-Small Cell Lung Cancer Patients Harboring Uncommon Mutations-The Mutation Patterns, Use of Different Generations of -TKIs, and Concurrent Genetic Alterations.具有罕见突变的晚期非小细胞肺癌患者的预测价值——突变模式、不同代-TKIs的使用及并发基因改变
Front Oncol. 2021 Aug 26;11:646577. doi: 10.3389/fonc.2021.646577. eCollection 2021.
7
Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.TP53 并发突变对晚期非小细胞肺癌 EGFR-TKIs 和 ALK-TKIs 靶向治疗的预后价值：一项荟萃分析。
BMC Cancer. 2020 Apr 16;20(1):328. doi: 10.1186/s12885-020-06805-5.
8
Uncommon mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy.一组中国非小细胞肺癌患者的罕见突变以及一线表皮生长因子受体酪氨酸激酶抑制剂和铂类化疗的结果
Chin J Cancer Res. 2017 Dec;29(6):543-552. doi: 10.21147/j.issn.1000-9604.2017.06.09.
9
Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.携带EGFR突变的晚期非小细胞肺癌靶向治疗的耐药性：从机制分析到临床策略
J Cancer Res Clin Oncol. 2021 Dec;147(12):3653-3664. doi: 10.1007/s00432-021-03828-8. Epub 2021 Oct 18.
10
Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer.基于免疫治疗的联合策略治疗 EGFR-TKI 耐药的非小细胞肺癌。
Future Oncol. 2022 May;18(14):1757-1775. doi: 10.2217/fon-2021-0862. Epub 2022 Mar 2.
本文引用的文献
1
Treatment of Rare Mutations in Patients with Lung Cancer.肺癌患者罕见突变的治疗
Biomedicines. 2021 May 11;9(5):534. doi: 10.3390/biomedicines9050534.
Zotero 插件